Behavioural Study in Chronic Pain : Creativity and Motivation, and Circuits Involved in Functional MRI
AART
1 other identifier
interventional
48
0 countries
N/A
Brief Summary
Being creative means having the ability to produce ideas, actions or works that are original and different from what we have already done. This process involves mental flexibility, in particular the association of distant ideas or divergent thinking. This creative potential is complex and depends on a number of factors, both internal (personality, motivation, emotional state, stress) and external to the individual (socio-cultural context). The generation of creative ideas involves the fronto-striatal circuit, with a balance between flexibility and perseverance. The striatum is central to the reward system and mental flexibility, while the prefrontal cortex is involved in executive control, underpinning perseverance functions. Dopamine plays a key role in this balance, and changes in dopamine levels, depending on the type of receptor activated, will have a direct impact on the transition between mental flexibility and perseverance. Furthermore, in the context of chronic pain, changes in connectivity and activity can be observed in neuroimaging in these same regions of the reward circuit. This suggests that the dopaminergic system is also involved in the chronicisation of pain. The creative process would therefore be correlated with the dopaminergic reward system, involving several dimensions, both cognitive in terms of mental flexibility, coping strategies and perseverance, and motivational. In this context, art therapy treatments are beginning to be studied, particularly in patients suffering from Alzheimer's or Parkinson's disease, showing improvements in anxiety and depression. Art therapy has not yet been widely proposed or studied for patients suffering from chronic pain. A more detailed behavioural study would confirm and clarify the clinical benefits for patients, by exploring the neuronal circuits involved, particularly the dopaminergic reward system.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_3 chronic-pain
Started Sep 2025
Longer than P75 for phase_3 chronic-pain
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 9, 2024
CompletedFirst Posted
Study publicly available on registry
July 16, 2024
CompletedStudy Start
First participant enrolled
September 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 1, 2029
June 11, 2025
June 1, 2025
3.3 years
July 9, 2024
June 6, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
changes in performance to obtain a reward (reward-based learning task) between before the sessions and 1 to 2 weeks after the sessions
the reward learning ability will be assessed using a specific task. The result of the task questionnaire is a numeric score.
Day0 and 1 to 2 weeks after the last session
Study Arms (2)
art-therapy
EXPERIMENTALArt therapy workshops : groups of 6 to 12 patients supervised over a session of 1.5 to 2 hours, in the presence of an artist and the nursing staff (psychologist, nurse, doctor). There are 6 sessions per group, with an average of one week between sessions.
relaxation
ACTIVE COMPARATORRelaxation workshops (control group): groups of 6 to 12 patients supervised over a session of 1.5 to 2 hours, in the presence of the psychologist. 5 sessions per group, with an average of one week between sessions.
Interventions
Over the 6 sessions, different artistic techniques will be explored, depending on the artist leading the workshop: stencil, graffiti, spray paint, collage, oil pastel, calligraphy and acrylic doodling. A collective work may also be proposed.
Eligibility Criteria
You may qualify if:
- Patient aged 18 and over
- Consent to participate in the study
- Available for protocol visits
- Treated for chronic pain
You may not qualify if:
- Progressive neurodegenerative neurological pathology impairing cognitive function
- Untreated clinical depressive syndrome
- Fibromyalgia in the foreground
- High doses of opioid treatment (greater than 100 mg/d of morphine equivalent)
- Impaired judgement or inability to receive information that prevents performance of behavioural tasks
- Absolute contraindication to MRI (e.g. pacemaker and implantable stimulator not MRI compatible, intra-orbital metallic foreign body);
- Persons benefiting from a legal protection measure
- Pregnant or breast-feeding women
- Patient deprived of liberty
- Patient suffering from mental disorders
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Masking Details
- In order to limit biases linked to the absence of blinding and to potential patient preferences for one or other of the interventions, a "consent to postponed information" type of consent (Boter et al. 2003) will be used.
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- NETWORK
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 9, 2024
First Posted
July 16, 2024
Study Start
September 1, 2025
Primary Completion (Estimated)
January 1, 2029
Study Completion (Estimated)
January 1, 2029
Last Updated
June 11, 2025
Record last verified: 2025-06
Data Sharing
- IPD Sharing
- Will not share